The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
A bipartisan group of state health policymakers from both the executive and legislative branches who are focused on improving population health.
Networks of state officials, advocates, and others aiming to invest in and transform primary care.
A program dedicated to advancing state-based efforts to make health care more affordable for residents, employers, and states.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
A leadership development program for early and mid-career state government officials who are committed to improving the health of all people in their communities.
A leadership program for senior state government officials who are committed to improving population health.
The Fund focuses on creating an affordable health care system built on strong primary care and partnerships that improve health outcomes for all.
Improving state leaders’ ability to enact and implement evidence-based health policies.
Advancing policies that create a more prevention- and primary care-oriented health system.
Improving population health through policies that contain health care cost growth.
Our state health policy resources offer relevant data analysis and best practices.
The Fund publishes reports, issues briefs, and case studies on state health policy issues.
Short takes on health policy issues from Milbank staff and guest authors.
Insights from Milbank President Debra Lubar on state health policymaking.
Reported articles and Q&As on timely health policy issues, as well as foundation updates.
Milbank Memorial Fund and Milbank Quarterly webinars featuring state health policymakers and researchers.
Updates and expert contact information for reporters.
The Milbank Memorial Fund is a private foundation that works to improve population health and health equity.
June 2021 (Volume 99)
Quarterly Article
Zackary Berger
Vivian V. Altiery De Jesus
Sabrina A. Assoumou
Trisha Greenhalgh
December 2024
June 2024
The Future of Population Health
Back to The Milbank Quarterly
Policy Points:
The pandemic has highlighted and exacerbated health inequities in both acute coronavirus disease 2019 (COVID-19) and its longer-term sequelae. Symptoms of COVID-19 persist in approximately one in 10 patients. Acute symptoms include shortness of breath, cough, myalgias, disturbances in the sense of taste and smell, fatigue, fever, chills, and, less commonly, rhinitis and gastrointestinal symptoms. By contrast, the term “long COVID,” coined by patients, refers to both postacute symptoms (lasting more than three weeks) and chronic symptoms (lasting more than 12 weeks). Long COVID is a multisystem disease of unknown cause whose manifestations, while partially overlapping the acute presentation, vary widely among patients and are exacerbated by comorbidities and vulnerabilities. It occurs in adults who were hospitalized and those who were not and (more rarely) in children. At the time of this writing, the United States had more than 17 million diagnosed cases of COVID-19, which translates into approximately 1,700,000 people with long COVID. This does not include the likely underreporting of COVID-19 cases, the proportion of which in one study ranged from one in three to one in 406. The implications for health services are substantial. Given the heterogeneity in definitions of long COVID and the lack of centralized registries of patients with the disease, those who might suffer from long-term symptoms might mistakenly be recorded as recovered.
The natural history of long COVID appears to be gradual improvement over time in most cases, though recovery is typically measured in months. Some patients require comprehensive assessment to exclude serious complications that might underlie their symptoms (notably, thrombo-embolic disease of the lungs, heart, and brain), along with holistic clinical intervention and follow-up. Patients without concerning symptoms should be supported but spared overinvestigation and overmedicalization. Those who have survived admission to an intensive care unit and those with preexisting respiratory, cardiovascular, or cerebrovascular disease are likely to require more specialized and prolonged rehabilitation. Given the paucity of evidence, it is currently unclear which of these issues related to long COVID are directly related to or caused by the disease itself and which are unrelated but may be made more difficult to treat owing to COVID-19 and its after-effects.